A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity

Cancer Cell International

Review

Andrés Alexis Ramírez-Coronel¹  Fahad Alsaikhan²  Mustafa M. Kadhim³  Zanko Hassan Jawhar⁴  Bagher Farhood⁵  Mandeep Singh⁶  Zafar Aminov⁷  Abduladheem Turki Jalil⁸  Shamam Kareem Oudah⁹ 

[1] Azogues Campus Nursing Career, Health and Behavior Research Group (HBR), Psychometry and Ethology Laboratory, Catholic University of Cuenca, Cuenca, Ecuador;Epidemiology and Biostatistics Research Group, CES University, Medellín, Colombia;Educational Statistics Research Group (GIEE), National University of Education, Cuenca, Ecuador;College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia;Department of Dentistry, Kut University College, 52001, Kut, Wasit, Iraq;Medical Laboratory Techniques Department, Al-Farahidi University, 10022, Baghdad, Iraq;Department of Medical Laboratory Science, College of Health Sciences, Lebanese French University, Erbil, Kurdistan Region, Iraq;Clinical Biochemistry Department, College of Health Sciences, Hawler Medical University, Erbil, Kurdistan Region, Iraq;Department of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran;Department of Physical Education, University of Jammu, Srinagar, Jammu, India;Department of Public Health and Healthcare Management, Samarkand State Medical University, 18 Amir Temur Street, Samarkand, Uzbekistan;Department of Scientific Affairs, Tashkent State Dental Institute, 103 Makhtumkuli Str., Tashkent, Uzbekistan;Medical Laboratories Techniques Department, Al-Mustaqbal University College, 51001, Babylon, Hilla, Iraq;National University of Science and Technology, Nasiriyah, Dhi Qar, Iraq;

关键词: Cancer;    Cardiotoxicity;    Doxorubicin;    Silymarin;    Silibinin;    Systematic review;   

DOI  :  10.1186/s12935-023-02936-4

 received in 2023-01-17, accepted in 2023-05-03,  发布年份 2023

来源: Springer

【 摘 要 】

PurposeAlthough doxorubicin chemotherapy is commonly applied for treating different malignant tumors, cardiotoxicity induced by this chemotherapeutic agent restricts its clinical use. The use of silymarin/silibinin may mitigate the doxorubicin-induced cardiac adverse effects. For this aim, the potential cardioprotective effects of silymarin/silibinin against the doxorubicin-induced cardiotoxicity were systematically reviewed.MethodsIn this study, we performed a systematic search in accordance with PRISMA guideline for identifying all relevant studies on “the role of silymarin/silibinin against doxorubicin-induced cardiotoxicity” in different electronic databases up to June 2022. Sixty-one articles were obtained and screened based on the predefined inclusion and exclusion criteria. Thirteen eligible papers were finally included in this review.ResultsAccording to the echocardiographic and electrocardiographic findings, the doxorubicin-treated groups presented a significant reduction in ejection fraction, tissue Doppler peak mitral annulus systolic velocity, and fractional shortening as well as bradycardia, prolongation of QT and QRS interval. However, these echocardiographic abnormalities were obviously improved in the silymarin plus doxorubicin groups. As well, the doxorubicin administration led to induce histopathological and biochemical changes in the cardiac cells/tissue; in contrast, the silymarin/silibinin co-administration could mitigate these induced alterations (for most of the cases).ConclusionAccording to the findings, it was found that the co-administration of silymarin/silibinin alleviates the doxorubicin-induced cardiac adverse effects. Silymarin/silibinin exerts its cardioprotective effects via antioxidant, anti-inflammatory, anti-apoptotic activities, and other mechanisms.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_36_Article_IEq23.gif

41116_2023_36_Article_IEq15.gif